Literature DB >> 22454872

Effects on the human central nervous system of two isomers of ephedrine and triprolidine, and their interaction.

C Bye1, D Dewsbury, A W Peck.   

Abstract

1 D(-)ephedrine is four times as potent as L(+)pseudoephedrine in producing both tachycardia and a rise in systolic blood pressure. No changes in diastolic blood pressure occurred in 12 subjects with doses of up to D(-)ephedrine (50 mg) and L(+)pseudoephedrine (180 mg). 2 Significant evidence of stimulation of the central nervous system occurred only after D(-)ephedrine in that tapping rates were increased and subjects could reliably detect that they had received an active drug. While mean performance rates in an auditory vigilance test were higher following both ephedrine isomers these changes were not significant. 3 Impairment of both tapping rates and auditory vigilance occurred following triprolidine in another group of 12 subjects. The effect was generally related to dose of antihistamine given and lasted up to 7.25 hours. Subjective effects were reliably recognized by subjects following all treatments containing triprolidine (2.5 mg or more) for up to 4.75 hours. Using analogue lines for self rating the subjective effects following triprolidine indicated both mental and physical impairment differing significantly from scores after lactose and L(+)pseudoephedrine (60 mg). 4 Combination of triprolidine (2.5 mg) and L(+)pseudoephedrine (60 mg) produced effects similar to triprolidine alone on both subjective measures and the auditory vigilance test. It is suggested that these objective tests and subjective scales could be used to measure effects on the central nervous system produced by antihistamines together with similar drugs, and their interaction with other compounds administered concurrently.

Entities:  

Year:  1974        PMID: 22454872      PMCID: PMC1402412          DOI: 10.1111/j.1365-2125.1974.tb00209.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  A PHARMACOLOGICAL STUDY OF THE EPHEDRINE ISOMERS.

Authors:  P N PATIL; A TYE; J B LAPIDUS
Journal:  J Pharmacol Exp Ther       Date:  1965-05       Impact factor: 4.030

2.  A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests.

Authors:  C Bye; A D Munro-Faure; A W Peck; P A Young
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

3.  [Case of mental disorders due to chronic ephedrine abuse].

Authors:  J Bartoszewski; E Majewska
Journal:  Psychiatr Pol       Date:  1972 Nov-Dec       Impact factor: 1.657

4.  The action of sedatives on brain stem oculomotor systems in man.

Authors:  H Norris
Journal:  Neuropharmacology       Date:  1971-03       Impact factor: 5.250

5.  Ephedrine psychosis.

Authors:  C F Herridge; M F a'Brook
Journal:  Br Med J       Date:  1968-04-20

6.  [Hallucinosis in ephedrine addiction].

Authors:  H Prokop
Journal:  Nervenarzt       Date:  1968-02       Impact factor: 1.214

7.  Some neuropharmacological properties of the ephedrine isomers.

Authors:  G Lanciault; H H Wolf
Journal:  J Pharm Sci       Date:  1965-06       Impact factor: 3.534

  7 in total
  12 in total

1.  Elimination of ephedrines in urine following multiple dosing: the consequences for athletes, in relation to doping control.

Authors:  Neil Chester; David R Mottram; Thomas Reilly; Mark Powell
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Residual effects of hypnotic drugs: evidence for individual differences on vigilance.

Authors:  A W Peck; R Adams; C Bye; R T Wilkinson
Journal:  Psychopharmacologia       Date:  1976-05-28

3.  Effects of a sedative and of a non-sedative H1-antihistamine on the event-related potential (ERP) in normal volunteers.

Authors:  F M Swire; C A Marsden; C Barber; A T Birmingham
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Evidence for tolerance to the central nervous effects of the histamine antagonist, triprolidine, in man.

Authors:  C E Bye; R Claridge; A W Peck; F Plowman
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

5.  A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man.

Authors:  C Bye; H M Hill; D T Hughes; A W Peck
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

6.  A comparison of triprolidine and clemastine on histamine antagonism and performance tests in man: implications for the mechanism of drug induced drowsiness.

Authors:  A W Peck; A S Fowle; C Bye
Journal:  Eur J Clin Pharmacol       Date:  1975-08-14       Impact factor: 2.953

Review 7.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

8.  Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man.

Authors:  J Dickerson; D Perrier; M Mayersohn; R Bressler
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

Review 9.  Behavioural effects of histamine and its antagonists: a review.

Authors:  J M White; G R Rumbold
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  The effects upon vigilance and reaction speed of the addition of ephedrine hydrochloride to chlorpheniramine maleate.

Authors:  K Millar; R T Wilkinson
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.